新型活性调节剂PCC0104005的体内药效学研究

In vivo Pharmacodynamic Study of a Modulator PCC0104005

为了研究PCC0104005对精神分裂症的治疗作用,采用MK-801及5-HTP诱导大鼠精神分裂症模型进行体内药效学研究,同时检测药物是否容易出现锥体外系不良反应.实验结果显示,PCC0104005可以显著抑制MK-801诱导的大鼠运动机能亢进,拮抗5-HTP诱导的大鼠甩头反应,水迷宫检测发现PCC0104005可以显著缩短大鼠的逃避潜伏期.不良反应检测中,PCC0104005引起锥体外系不良反应的可能性较低. PCC0104005与一线抗精神分裂症药物相比非劣性,为精神分裂症的治疗提供新的候选药物.

In order to reveal the effect of PCC0104005 on the treatment of schizophrenia, MK-801 and 5-HTP induced schizophrenia model in rats is used to study the pharmacodynamics in vivo, and to detect whether the drug is prone to extrapyramidal adverse reactions. The results show that PCC0104005 can significantly inhibit MK-801-induced hyperactivity in rats and antagonize 5-HTP-induced rat head twitch. Morris water maze test reveals that PCC0104005 can significantly reduce the escape latency of rats. In adverse reaction detection, PCC0104005 is less likely to cause extrapyramidal adverse reactions. PCC0104005 is not inferior to the first-line anti-schizophrenia drugs and can be new candidates for the treatment of schizophrenia.